The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ACET | -41.92% | -96.95% | -50.19% | -97% |
| S&P | +20.12% | +68.19% | +10.95% | +96% |
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
These companies' share prices could rise in the short term, but their long-term opportunities are even better.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$1,473.00K | 9.2% |
| Market Cap | $80.65M | 1.5% |
| Market Cap / Employee | $790.70K | 0.0% |
| Employees | 102 | -32.9% |
| Net Income | -$30,516.00K | -6.2% |
| EBITDA | -$30,413.00K | -4.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $38.92M | -31.1% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $11.55M | -18.1% |
| Short Term Debt | $3.19M | 1.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -56.62% | -1.8% |
| Return On Invested Capital | -40.82% | -1.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$20,899.00K | 13.9% |
| Operating Free Cash Flow | -$20,909.00K | 13.2% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.39 | 0.38 | 0.62 | 0.40 | -5.71% |
| Price to Tangible Book Value | 5.35 | 5.00 | 8.09 | 0.40 | -93.31% |
| Enterprise Value to EBITDA | 2.54 | 2.13 | 2.05 | 0.45 | -75.16% |
| Return on Equity | -55.8% | -64.4% | -71.7% | -67.6% | 2.89% |
| Total Debt | $16.25M | $15.36M | $15.54M | $14.74M | -14.48% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
